Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An immunophilin-binding assay for sirolimus.

D L Davis1, S J Soldin

  • 1Department of Laboratory Medicine, Children's National Medical Center, Washington, DC 20010, USA.

Clinical Therapeutics
|May 24, 2000
PubMed
Summary

This review compares four methods for measuring sirolimus levels in blood. The goal was to find the best method based on six expert-defined criteria. The methods include HPLC-MS, MEIA, p70 S6 kinase inhibition, and the immunophilin-binding assay (IBA). The IBA uses a T-cell protein that binds to sirolimus and may be the drug’s intracellular target. This allows the IBA to measure sirolimus accurately, even when metabolites are present. The IBA was tested on over 200 samples and showed good agreement with HPLC results. It is also easier to perform and more precise than HPLC methods. MEIA overestimates concentrations due to cross-reactivity. p70 S6 kinase inhibition is still theoretical. The IBA appears to have clear advantages over the other methods and may be a better option for clinical use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preliminary study on the impact of 900 MHz radiation on human sperm: An in vitro molecular approach.

Reproductive toxicology (Elmsford, N.Y.)·2024
Same author

Diurnal variation of steroid hormones and their reference intervals using mass spectrometric analysis.

Endocrine connections·2018
Same author

Absorption of wireless radiation in the child versus adult brain and eye from cell phone conversation or virtual reality.

Environmental research·2018
Same author

Does TSH Reliably Detect Hypothyroid Patients?

Annals of thyroid research·2018
Same author

Brain-derived neurotrophic factor Val<sup>66</sup>Met genotype and ovarian steroids interactively modulate working memory-related hippocampal function in women: a multimodal neuroimaging study.

Molecular psychiatry·2017
Same author

The newfoundland change of life: Insights into the medicalization of menopause.

Journal of cross-cultural gerontology·2014

Area of Science:

  • Clinical pharmacology and therapeutic monitoring
  • Immunosuppressive drug analysis
  • Analytical chemistry in drug development

Background:

There is a need for accurate and practical methods to measure sirolimus levels in clinical settings. Prior research has shown that sirolimus monitoring is essential for managing immunosuppressive therapy in transplant patients. However, no prior work had resolved the limitations of current assays in terms of precision, ease of use, and selectivity. Existing methods face challenges such as complex preparation steps and cross-reactivity with metabolites. These issues may affect the reliability of concentration measurements. The gap in reliable, selective, and user-friendly assays motivated the evaluation of four available techniques. Researchers aimed to determine which method best meets expert-defined guidelines. This uncertainty drove the need for a comparative assessment of available methodologies.

Purpose Of The Study:

The aim of this review is to assess the performance of four sirolimus assays against six expert-defined guidelines. The specific problem is the lack of a reliable, clinically practical method for measuring sirolimus in whole blood. The motivation stems from the need for accurate monitoring to optimize therapeutic outcomes. The researchers propose that an assay must meet precision, ease of use, and selectivity criteria. The study focuses on comparing HPLC-MS, MEIA, p70 S6 kinase inhibition, and IBA. These methods were evaluated for their ability to overcome current limitations in sirolimus testing. The review approach involves analyzing published data on each method's strengths and weaknesses. This analysis helps identify the most suitable assay for clinical application.

Keywords:
sirolimus testingimmunophilin assaydrug monitoring methodsclinical pharmacology

Frequently Asked Questions

The IBA uses a T-cell protein that binds selectively to sirolimus, allowing it to distinguish the drug from structurally similar metabolites.

MEIA may overestimate sirolimus concentrations due to antibody cross-reactivity with the drug’s metabolites.

IBA requires less specimen preparation and is more precise, making it more practical for routine clinical use.

The T-cell protein may represent the intracellular target of sirolimus and is used as the binding agent in the IBA.

Related Experiment Videos

Main Methods:

The review approach involved a MEDLINE search to gather relevant studies on sirolimus assays. Four methods were evaluated: HPLC-MS, MEIA, p70 S6 kinase inhibition, and IBA. Each method was assessed for its adherence to six expert-defined guidelines. The researchers analyzed the precision and practicality of each technique. They examined issues such as cross-reactivity and specimen preparation. The IBA uses a T-cell protein as the binding agent, which may represent the drug’s intracellular target. Data from over 200 clinical samples were used to evaluate the IBA's performance. The study compared IBA results with HPLC values to assess correlation and accuracy.

Main Results:

The IBA demonstrated good correlation with HPLC values, with a regression line slope near 1.0. This suggests that IBA measurements align closely with those from HPLC. The IBA was found to be more precise than HPLC methods, which suffer from preparation-related variability. The assay is easier to perform and has the potential for automation. The IBA uses a T-cell protein that binds selectively to sirolimus. This selectivity allows the assay to distinguish sirolimus from structurally similar metabolites. MEIA was found to overestimate concentrations due to antibody cross-reactivity. p70 S6 kinase inhibition remains theoretical and not yet optimized for clinical use.

Conclusions:

The IBA appears to have clear advantages over other sirolimus assays. The authors propose that the IBA offers better precision and ease of use compared to HPLC methods. The selectivity of the IBA in the presence of metabolites is a key benefit. The assay's potential for automation supports its suitability for clinical settings. The IBA's performance with over 200 samples suggests reliability in real-world applications. The authors suggest that the IBA meets more expert guidelines than the other methods. The study supports the IBA as a promising alternative to current techniques. These findings may influence future choices in sirolimus monitoring.

The IBA was tested on more than 200 clinical samples, showing good correlation with HPLC values and a regression line slope near 1.0.

The authors propose that the IBA may become a preferred method due to its precision, ease of use, and potential for automation.